PROTAC treatment for HIV06285PROTACs selectively degrade HIV Nef, restoring immune recognition and suppressing HIV replication, aiming for reservoir clearance.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasInfectious DiseaseLead InventorThomas SmithgallDepartmentMed-Microbiology and Molecular GeneticsAll Tech InnovatorsLori Ann Emert-SedlakAllen B. ReitzThomas E. SmithgallTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2023-02-06
Innovative Small Molecule for Zika Virus Neutralization06214CZV1-1: first nonpeptide Zika neutralization surrogate enabling highly specific, room-temperature diagnostics and research tools.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasInfectious DiseaseTherapeutic IndicationsZikaLead InventorDonald BurkeDepartmentGSPH-EpidemiologyAll Tech InnovatorsDonald S. BurkePriscila Mayrelle Da Silva CastanhaErnesto Torres De Azeved Marques JrDate Submitted2022-11-14CollectionsWomen's & Reproductive Health
Heparanase Inhibition for Organ Preservation05953HPSE inhibitors added to ex vivo lung perfusion preserve endothelial glycocalyx, boost graft quality and transplant outcomes. (15 words)Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasImmunologyLead InventorPablo SanchezDepartmentMed-Cardiothoracic SurgeryAll Tech InnovatorsKentaro NodaPablo Gerardo SanchezDate Submitted2022-02-03
Small Molecule Allosteric Modulators of Class B GPCRs in the PTHR and Method to Identify Them05559Structure-guided discovery yields four small-molecule negative allosteric modulators of PTHR, offering oral, targeted osteoporosis therapy.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasMusculoskeletalEndocrinology and Metabolic DiseasesLead InventorIeva SutkeviciuteDepartmentMed-Pharmacology and Chemical BiologyAll Tech InnovatorsIvet BaharPemra DorukerJiyoung LeeTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2020-11-19CollectionsCardiometabolicWomen's & Reproductive Health
Novel Compounds to Inhibit TNF-Induced NF-κB Pathways04864Network-centric discovery yields two first-in-class small molecules selectively blocking TNF-induced NF-κB signaling, reducing off-target effects.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasImmunologyTagsAutoimmuneLead InventorCarlos CamachoDepartmentMed-Computational and Systems BiologyAll Tech InnovatorsCarlos Jaime CamachoRobin E C LeeDate Submitted2019-01-22
Small Molecule Drug for Targeting Resistant Prostate Cancer07323New CPPI-derived small molecules act as nuclear androgen receptor degraders, suppressing resistant prostate cancer in AR-positive tumors.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyTagsLife ScienceOncologyLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsTimothy James CasadJoel B. NelsonZhou WangDate Submitted2025-09-02
Dipeptidyl Peptidase-4 (DPP4) Inhibitors for Inhibiting Posterior Capsular Opacification07055DPP4 inhibitors delivered locally prevent posterior capsular opacification by blocking TGF-β–driven EMT in lens cells.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOphthalmologyTherapeutic IndicationsCataractsTagsAgingDrug RepurposingLead InventorKun Che ChangDepartmentMed-OphthalmologyAll Tech InnovatorsKun Che ChangChi-Yu ChenPei-Kang LiuTechnology Readiness Level4. Pre-clinical developmentDate Submitted2025-01-31CollectionsRegenerative Medicine
Novel Therapy for Chondrocyte Aging and Osteoarthritis07004GATA4-targeting small molecule HCA42027 may restore aged chondrocyte repair, offering a potential disease-modifying OA therapy.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasCardiovascularMusculoskeletalTherapeutic IndicationsHeart failureAtherosclerotic diseaseOsteoarthritisTagsDrug Discovery - TargetLife ScienceLead InventorHang LinDepartmentMed-Orthopedic SurgeryAll Tech InnovatorsOlivia BartholomewKate LiHang LinDate Submitted2024-12-11CollectionsCardiometabolic
Targeted HDAC 8 Inhibitors for Managing Kidney Disease06617Indole-based HDAC-8 inhibitors offer targeted, potentially less toxic kidney disease therapy; prototype-stage, organoid-supported efficacy.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNephrologyTherapeutic IndicationsAcute Kidney Injury (AKI)Lead InventorDonna HurynAll Tech InnovatorsNeil A. HukriedeDonna HurynSangeetha SubramaniDate Submitted2024-01-26
Novel Glutamate Receptor Agonists06272Glutamate receptor agonist SYM2081 dampens dermal mast cell activation, offering potential treatments for dermatitis, rosacea, and hypersensitivity.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasDermatologyTherapeutic IndicationsDermatitisLead InventorDaniel KaplanDepartmentMed-DermatologyAll Tech InnovatorsDaniel H. KaplanTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2023-01-24
NAMPT Inhibitors Exhibit Excellent Potency and ADME Properties05522Novel Nampt inhibitors deliver strong potency and favorable ADME, enabling chemotherapy and immune support benefits.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasImmunologyOncologyTagsAutoimmuneImmuno-oncologyLead InventorBeibei ChenDepartmentMed-MedicineAll Tech InnovatorsBeibei ChenToren FinkelYuan LiuTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2020-10-06
Mitoparib: A Mitochondrial PARP Inhibitor that Counteracts Metabolic Stress03916Mitochondria-targeted PARP inhibitor that preserves mitochondrial NAD+, preventing stress-induced necrosis without hindering nuclear DNA repair.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsHulya BayirRobert B. ClarkTanja KrainzTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2016-04-23
Borylated Esters and Acetals as Cancer Prodrugs06731Boronate-protected prodrugs release cytotoxins in peroxide-rich cancer cells, enabling targeted, reduced-side-effect chemotherapy.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyTagsLife ScienceLead InventorPaul FloreancigDepartmentChemistryAll Tech InnovatorsAlexander DeitersPaul Edward FloreancigPaul Joseph GeaneotesDate Submitted2024-04-29
HIF1 Activators as Therapeutics for Triosephosphate Isomerase Deficiency (TPI Df)07001HIF1-activating triazines boost TPI expression, repurposing approved PHD inhibitors (e.g., vadadustat) for TPI deficiency.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasMusculoskeletalLead InventorMichael PalladinoDepartmentMed-Pharmacology and Chemical BiologyAll Tech InnovatorsMichael John PalladinoAndreas VogtDate Submitted2024-12-09
Nitro-fatty Acids for Treating Aortic Aneurysm05302Nitro-oleic acid (nitro-fatty acid) shows promise halting abdominal aortic aneurysm progression via anti-inflammatory effects.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasCardiovascularTherapeutic IndicationsOtherLead InventorFrancisco SchopferDepartmentMed-Pharmacology and Chemical BiologyAll Tech InnovatorsYuqing Eugene ChenBruce A. FreemanFrancisco Jose Schopfer PhDDate Submitted2020-04-13CollectionsCardiometabolic
Next Generation Targeted Nitroxides05064Nitroxide-based lipids curb lipid peroxidation to mitigate ferroptosis, aiming at ischemia injury, AKI, and neuroprotection.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasEndocrinology and Metabolic DiseasesNephrologyTherapeutic IndicationsAcute Kidney Injury (AKI)Lead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsPeter WipfDate Submitted2019-07-20CollectionsCardiometabolic
Universal Vaccine for SARS-CoV-2 (COVID 19)05356Universal vaccine approach targets SARS-CoV-2 RdRp activation motif, potentially halting replication across coronaviruses.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasInfectious DiseaseTherapeutic IndicationsCovid-19Lead InventorPatrick MooreDepartmentMed-PathologyAll Tech InnovatorsYuan ChangPatrick S. MooreMasahiro ShudaDate Submitted2020-05-13
Novel Treatment for Retinitis Pigmentosa06383Pyrvinium targets NS LLPS to restore proteostasis, preserve retinal structure, and may treat retinitis pigmentosa and proteinopathies.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNeuroscienceOphthalmologyTherapeutic IndicationsParkinson's DiseaseAlzheimer's DiseaseRetinitis pigmentosa (RP)TagsLife ScienceLead InventorBokai ZhuDepartmentMed-MedicineAll Tech InnovatorsYuanyuan ChenWilliam A. DionBokai ZhuDate Submitted2023-04-23
Novel Approach to Bone Regeneration06099Activates skeletal stem cells to regenerate bone endogenously, using mechanical suture expansion and niclosamide-based stimulation.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasDentalMusculoskeletalTherapeutic IndicationsOsteoporosisTagsRegenerative medicineLead InventorGiuseppe IntiniDepartmentDent Med-Periodontics/Preventive DentistryAll Tech InnovatorsXue Hui GengGiuseppe IntiniLuigi MancinelliTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2022-07-13CollectionsRegenerative MedicineWomen's & Reproductive Health
Antioxidant Therapy for Treating Propionic and Methylmalonic Acidemia05544Mitochondria-targeted antioxidants offer a non-invasive therapy to lower reactive oxygen, mitigating damage in propionic and methylmalonic acidemia.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasEndocrinology and Metabolic DiseasesTherapeutic IndicationsOtherMitochondrial DiseaseTagsPediatricsRare diseaseLead InventorGerard VockleyDepartmentMed-PediatricsAll Tech InnovatorsGerard VockleyPeter WipfTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2020-10-30CollectionsRare DiseasesCardiometabolic
RNF167 and CASTOR1 as Novel mTOR Targets05450Novel RNF167-CASTOR1 axis activates mTORC1, promoting cancer; potential drug targets and prognostic biomarkers.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyLead InventorShou-Jiang GaoDepartmentMed-Microbiology and Molecular GeneticsAll Tech InnovatorsShou-Jiang GaoTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2020-07-16CollectionsWomen's & Reproductive Health
Novel Small Molecules for Inhibition of MALT105186Innovative MALT1 inhibitors block both protease and scaffolding functions, expanding cancer and autoimmune therapy potential.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasImmunologyOncologyTagsAutoimmuneImmuno-oncologyLead InventorPeter LucasDepartmentMed-PathologyAll Tech InnovatorsBeibei ChenDong HuHeejae KangTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2019-11-30CollectionsWomen's & Reproductive Health
Novel Glycine Receptor Modulators for Analgesia04250Glycine receptor modulators offer THC-like analgesia without psychoactivity, enabling opioid-sparing pain relief and inflammation targeting.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNeuroscienceLead InventorYan XuDepartmentMed-Anesthesiology and Perioperative MedicineAll Tech InnovatorsPei TangMarta Megan WellsYan XuTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2017-05-17
Novel Class Therapeutic Psychedelics05753Novel clavine psychedelics: total synthesis enables SAR-driven development of non-hallucinogenic, CNS-targeting therapeutic candidates.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasMental and Behavioral HealthTherapeutic IndicationsDepressionLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsEthan James PazurNikhil Rushi TaskerPeter WipfTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2021-07-02
New Approach to Combat Lithium-Induced Diabetes Insipidus04699Nrf2 activation via Bardoxolone methyl offers a novel Li-NDI therapy, reducing polyuria/polydipsia and protecting kidney health.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNephrologyEndocrinology and Metabolic DiseasesTherapeutic IndicationsChronic Kidney Disease (CKD)DiabetesLead InventorFrancisco SchopferDepartmentMed-Pharmacology and Chemical BiologyAll Tech InnovatorsSoma JobbagyFrancisco Jose Schopfer PhDDario A. Vitturi IglesiasDate Submitted2018-08-02CollectionsCardiometabolic
Enhancing the Activity of Cancer-targeting Immune Cells06446AMPK agonist c991 boosts oxidative T cell metabolism during CAR T preparation, enhancing anti-leukemia efficacy in vivo.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyTherapeutic IndicationsChronic Myeloid Leukemia (CML)Chronic Lymphocytic Leukemia (CLL)Acute Myeloid Leukemia (AML)Lead InventorCraig ByersdorferDepartmentMed-PediatricsAll Tech InnovatorsErica BravermanCraig Alan ByersdorferTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2023-07-02
Novel Activators of AMP-activated Protein Kinase03887New nanomolar small molecules block AMPK ubiquitination, stabilizing and activating AMPK to treat metabolic, inflammatory, and cancer disorders.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasCardiovascularEndocrinology and Metabolic DiseasesTagsAgingLead InventorBeibei ChenDepartmentMed-MedicineAll Tech InnovatorsBeibei ChenYuan LiuRama K. MallampalliTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2016-04-05CollectionsCardiometabolic
Novel Carbamates as Treatment for Tinnitus03415Potent, selective carbamates target KCNQ2/3 channels to reduce tinnitus and potentially treat epilepsy, via auditory synapse modulation.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOtolaryngologyLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsAthanassios TzounopoulosPeter WipfTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2014-10-03
Compounds Targeting Androgen Receptor to Treat Castration-Resistant Prostate Cancer02501Novel compounds degrade androgen receptor in the nucleus, inhibiting AR signaling and CRPC tumor growth without cytotoxicity.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaLead InventorZhou WangDepartmentMed-UrologyAll Tech InnovatorsPaul A. JohnstonJohn S. LazoJoel B. NelsonTechnology Readiness Level5. Drug candidate createdDate Submitted2011-06-10
Novel Mitochondrial Targeting Nitroxides for Radioprotection and the Treatment of Associated Pathologies02662Mitochondria-targeted nitroxide JP4-039 shields tissue from ROS and radiation, aiding healing with topical/oral delivery.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasEndocrinology and Metabolic DiseasesLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsPeter WipfTechnology Readiness Level4. Pre-clinical developmentDate Submitted2012-04-11CollectionsRegenerative MedicineCardiometabolic
Novel Senotherapeutic Agents for Cancer Therapy06267Senotherapeutic sGC activator cinaciguat induces apoptosis in senescent prostate cancer cells, reducing recurrence and BPH progression.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasUrologyOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaTagsAgingLead InventorAnthony KanaiDepartmentMed-MedicineAll Tech InnovatorsYouko IkedaAnthony J. KanaiIrina Valerjevna ZabbarovaTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2023-01-12
Profilin1-actin Interaction Inhibitor as a Novel Anti-Angiogenic Compound05290Profilin1–actin interaction inhibitor blocks ccRCC angiogenesis, offering a resistance-evading, low-toxicity anti-angiogenic cancer therapy.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyOphthalmologyTherapeutic IndicationsDiabetic retinopathyAge-related macular degenerationTagsPlatform TechnologyLead InventorPartha RoyDepartmentBioengineeringAll Tech InnovatorsPaul G. FrancoeurDavid Martin GauAbigail GondringerTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2020-04-09
Pfn1 as a Novel Therapeutic Target for Atherosclerosis06880Pfn1 inhibitors block actin interaction, offering a novel anti-atherosclerosis approach with anti-angiogenic potential.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasCardiovascularTherapeutic IndicationsAtherosclerotic diseaseLead InventorDavid GauDepartmentMed-PathologyAll Tech InnovatorsDavid Martin GauAbigail GondringerDonna HurynDate Submitted2024-09-17CollectionsCardiometabolic
Enzyme Inhibitor Promotes Anticancer Immune Response05716Enzyme ALDH1A inhibitor boosts antitumor immunity, enhances vaccine efficacy, and improves tumor control in hard-to-treat cancers.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasInfectious DiseaseOncologyTagsImmuno-oncologyLead InventorRonald BuckanovichDepartmentMed-MedicineAll Tech InnovatorsRonald J. BuckanovichAnda Mioara VladTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2021-06-08CollectionsWomen's & Reproductive Health
Novel Approach for Cartilage Repair05596Wnt inhibitors with microfracture improve cartilage repair by promoting hyaline cartilage and reducing fibrosis, via targeted intra-articular delivery.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasMusculoskeletalTherapeutic IndicationsOtherLead InventorHang LinDepartmentMed-Orthopedic SurgeryAll Tech InnovatorsHang LinDate Submitted2021-01-18CollectionsRegenerative Medicine
NKCC Inhibitors for Neuroprotection Following a Stroke04461Novel brain-targeted NKCC1 inhibitors (e.g., STS66) outperform bumetanide, reducing stroke damage while limiting diuretic side effects.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNeuroscienceLead InventorDandan SunDepartmentMed-NeurologyAll Tech InnovatorsThomas ErkerPhilipp SchreppelDandan SunTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2018-01-10
Targeting Genetic Changes in IDH-Mutant Gliomas with a Novel Use of an FDA-Approved Drug04124FDA-approved drug repurposed to target IDH-mutant gliomas, boosting immune recognition and shrinking tumors in animals and humans.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyLead InventorNdukaku AmankulorDepartmentMed-Neurological SurgeryAll Tech InnovatorsNdukaku Mgbechinyere AmankulorAparna Vijaykumar RaoTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2017-01-10
Novel Nitro Nitrate Lipid Intermediates that Mediate Nitrosating and Alkylating Reactions03996Nitro-nitrate-lipid intermediates act as versatile NO donors, offering vasodilation with dual nitrosating/alkylating actions for CVD therapy.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasCardiovascularLead InventorMarco FazzariDepartmentMed-Pharmacology and Chemical BiologyAll Tech InnovatorsMarco FazzariBruce A. FreemanFrancisco Jose Schopfer PhDDate Submitted2016-07-19CollectionsCardiometabolic
p97 ATPase Inhibitors for Cancer and Neurodegneration03811Allosteric p97 inhibitors selectively impair cancer and neurodegenerative pathways by blocking p97 ATPase function.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNeuroscienceLead InventorDonna HurynAll Tech InnovatorsDonna HurynMatthew G. LaPortePeter WipfTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2016-01-26
Novel Therapy to Prevent Organ Transplant Rejection06909WS6 inhibitor targets tissue-resident memory T cells, potentially preventing organ transplant rejection with reduced broad immunosuppression.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasImmunologyTherapeutic IndicationsOtherTagsDrug Discovery - TargetLife ScienceLead InventorKhodor Abou DayaDepartmentMed-SurgeryAll Tech InnovatorsKhodor Abou DayaDate Submitted2024-10-01
Targeted Protein Degradation through Site-Specific Recruitment of Ubiquitin Ligase06399Site-specific E3 ligase recruitment enables PROTAC-like protein degradation without a small-molecule ligand, advancing targetability.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOtherLead InventorAlexander DeitersDepartmentDistinguished Faculty-Dietrich School of Arts and SciencesAll Tech InnovatorsAlexander DeitersOlivia Hanson ShadeTechnology Readiness Level1. Research ideaDate Submitted2023-05-08
A Novel Treatment for Metastatic Prostate Cancer06044Novel allosteric AR modulators found to disrupt AR-TIF2 signaling, offering potential treatment for metastatic castration-resistant prostate cancer.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaLead InventorPaul JohnstonDepartmentPharm-Pharmaceutical ScienceAll Tech InnovatorsCarlos Jaime CamachoAndrew P. HinckPaul A. JohnstonTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2022-06-01
New Methodology Increases NAMPT Activity for Treating Several Diseases including Autoimmune Conditions05563New NAMPT-activating compounds boost NAD+ to treat obesity, autoimmune disorders, aging, kidney injury, and cognitive decline.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyEndocrinology and Metabolic DiseasesTherapeutic IndicationsObesityLead InventorBeibei ChenDepartmentMed-MedicineAll Tech InnovatorsBeibei ChenToren FinkelYuan LiuTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2020-11-23CollectionsCardiometabolic
Glutaminase Inhibitors03304Novel glutaminase inhibitors starve cancer cells of glutamine, showing in vivo tumor suppression and potential TNBC therapy.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyTherapeutic IndicationsDuctal carcinoma (Breast cancer)Lead InventorLee McDermottDepartmentPharm-Pharmaceutical ScienceAll Tech InnovatorsPrema Chandrasekhar IyerLee Apostle McDermottTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2014-04-29CollectionsWomen's & Reproductive Health
A Simple, Effective, and Dual-Functional Drug Delivery Platform for Hydrophobic Agents03178Dual-functional PEG-FTS micellar system enhances solubility, targets tumors, and co-delivers hydrophobic anticancer drugs with reduced toxicity.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyLead InventorSong LiDepartmentPharm-Pharmaceutical ScienceAll Tech InnovatorsXiang GaoYixian HuangSong LiTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2013-11-22
Small Molecule Antagonists of HIV Nef Function02843Small molecule inhibitors block HIV Nef function, offering potential combination therapies to reduce resistance and toxicity.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasInfectious DiseaseTherapeutic IndicationsHIVLead InventorThomas SmithgallDepartmentMed-Microbiology and Molecular GeneticsAll Tech InnovatorsBilly W. DayLori Ann Emert-SedlakPrema Chandrasekhar IyerDate Submitted2012-07-25CollectionsWomen's & Reproductive Health
Using STAT5 Inhibitors for the Treatment of Cardiovascular Calcification05857STAT5 inhibitors halt cardiovascular calcification by disrupting RUNX2-driven osteogenesis in valve and vascular cells.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasMusculoskeletalCardiovascularLead InventorCynthia St HilaireDepartmentMed-MedicineAll Tech InnovatorsRolando A. CuevasCynthia L. St HilaireTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2021-10-27CollectionsCardiometabolic
Small Molecule Inhibitor Therapy to Prevent Aneurysm Formation, Growth, and Rupture05390Small molecule inhibitors block CXCL7-CXCR1/2 inflammation to prevent cerebral aneurysm formation, growth, and rupture.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasCardiovascularNeuroscienceLead InventorRobert FriedlanderDepartmentMed-Neurological SurgeryAll Tech InnovatorsMichael P. D'AngeloRobert Max FriedlanderWendy Fellows MayleTechnology Readiness Level4. Pre-clinical developmentDate Submitted2020-05-30CollectionsRegenerative MedicineCardiometabolic
Novel Thiadiazines as Heat Shock Protein Modulators and Anti-Huntington Disease Therapeutic Agents05177Novel thiadiazine modulators target Hsp70, offering potential Huntington and neurodegenerative disease therapies via protein homeostasis regulation.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNeuroscienceLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsJeffrey L. Brodsky Ph.D.Linh Khai NgoLeila TerrabTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2019-11-20
300 Novel CB1 Antagonists Hold Potential for new Treatments05523New, structurally distinct CB1 antagonists offer broad potential for metabolic therapies and weight management. 15 words max, 120-150 characters.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNeuroscienceEndocrinology and Metabolic DiseasesTherapeutic IndicationsObesityLead InventorBeibei ChenDepartmentMed-MedicineAll Tech InnovatorsBeibei ChenToren FinkelYuan LiuTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2020-10-06CollectionsCardiometabolic
